<DOC>
	<DOCNO>NCT00560820</DOCNO>
	<brief_summary>The primary purpose study evaluate effect deferasirox renal hemodynamics determine glomerular filtration rate ( GFR ) , renal plasma flow ( RPF ) filtration fraction ( FF ) .</brief_summary>
	<brief_title>Phase I Study Examine Effect Deferasirox Renal Hemodynamics β-thalassemia Patients With Transfusional Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion criterion : Male female patient ≥ 18 year age without prior history deferasirox treatment βthalassemia patient receive regular transfusion every 25 week Transfusion history ≥ 20 unit pack red blood cell Exclusion criterion : Abnormal renal function baseline ALT great 5 x ULN screen Patients underlie cardiac disease require continuous iron chelation therapy Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>β-thalassemia</keyword>
	<keyword>transfusional iron overload</keyword>
	<keyword>renal function</keyword>
	<keyword>renal biomarkers</keyword>
	<keyword>deferasirox</keyword>
</DOC>